Sight Sciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Sight Sciences, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 8% in 3 years; of every extra $100 of sales, $793 became extra profit. Higher than 96% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-70.9×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 77% of Healthcare companies in United States.
Cash Locked Ratio
$21For every $100 of sales, $21 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $26 tied up three years earlier.
Less money tied up than 55% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
1/3 · 3/3Sales grew in 1 of the last 3 years; profit grew in 3 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$793Sales grew 8% in 3 years; of every extra $100 of sales, $793 became extra profit.
Higher than 96% of Healthcare companies in United States.
Asset Productivity Ratio
+8% / -46%In 3 years sales changed by +8% while total assets changed by -46%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-62.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than 77% of Healthcare companies in United States.
Cash Cushion Ratio
+10%Cash, after subtracting all debt, equals 10% of its market value (net cash).
Higher than 51% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Sight Sciences, Inc. made a loss over the last year. Sight Sciences, Inc. owes $0.50 for every $1 it owns. Sight Sciences, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossSight Sciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
9.47The share price is 9.47 times Sight Sciences, Inc.'s book value per share, higher than 86% of Healthcare companies in United States.
Market cap
$501 MThe total market value of all of Sight Sciences, Inc.'s shares at today's price (share price × number of shares), larger than 55% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$53 MWhat Sight Sciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.96Net worth divided by the number of shares. The share price of $9.09 is 9.5 times this, which is the P/B above.
Return on equity (ROE)
-48.4%Sight Sciences, Inc. lost 48.4% of its shareholders' money over the last year, higher than 50% of Healthcare companies in United States.
Owes vs Owns
0.50×Sight Sciences, Inc. owes $0.50 for every $1 it owns (low), higher than 55% of Healthcare companies in United States.
Dividend yield
NoneSight Sciences, Inc. does not currently pay a dividend.
Revenue growth
-3%Revenue fell 3% in the year to Dec 2025, and grew 3% a year on average over 3 years.
Profit growth
LossSight Sciences, Inc. made a loss in each of the last two years.
Profit margin
-49.7%Sight Sciences, Inc. lost $50 for every $100 of revenue.
Interest cover
Not coveredSight Sciences, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashSight Sciences, Inc. held $51 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Sight Sciences, Inc.: $501 M ÷ $53 M (30 Jun 2026) = 9.5.
What is Sight Sciences, Inc.'s return on equity?
Sight Sciences, Inc. lost 48.4% of its shareholders' money over the last year, higher than 50% of Healthcare companies in United States.
How much does Sight Sciences, Inc. owe compared with what it owns?
Sight Sciences, Inc. owes $0.50 for every $1 it owns (low), higher than 55% of Healthcare companies in United States.
Does Sight Sciences, Inc. pay a dividend?
No. Sight Sciences, Inc. does not currently pay a dividend.
Is Sight Sciences, Inc.'s revenue growing?
Revenue fell 3% in the year to Dec 2025, and grew 3% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.